MXPA05010986A - Compuestos de n-[(piperazinil)hetaril]arilsulfonamida con afinidad para el receptor d3 de la dopamina. - Google Patents

Compuestos de n-[(piperazinil)hetaril]arilsulfonamida con afinidad para el receptor d3 de la dopamina.

Info

Publication number
MXPA05010986A
MXPA05010986A MXPA05010986A MXPA05010986A MXPA05010986A MX PA05010986 A MXPA05010986 A MX PA05010986A MX PA05010986 A MXPA05010986 A MX PA05010986A MX PA05010986 A MXPA05010986 A MX PA05010986A MX PA05010986 A MXPA05010986 A MX PA05010986A
Authority
MX
Mexico
Prior art keywords
alkyl
cycloalkyl
hetaryl
piperazinyl
haloalkyl
Prior art date
Application number
MXPA05010986A
Other languages
English (en)
Inventor
Sean C Turner
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MXPA05010986A publication Critical patent/MXPA05010986A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

La invencion se refiere a compuestos de N-[(piperazinil)hetaril]arilsulfonamida de la formula general (I) (ver formula (I)) en donde Q es un radical heteroaromatico bivalente de 6 miembros que posee 1 o 2 atomos de nitrogeno como miembros de anillo y que lleva opcionalmente uno o dos sustituyentes Ra seleccionado(s), independientemente entre ellos, entre halogeno, CN, NO2, CO2R4, COR5, alquilo C1-C4 y haloalquilo C1-C4; Ar es fenilo o un radical heteroaromatico de 6 miembros que posee 1 o 2 atomos de nitrogeno como miembros de anillo y que lleva opcionalmente uno o dos sustituyentes Rb seleccionados entre halogeno, NO2, CN, CO2R4, COR5, alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, cicloalquilo C3-C6, cicloalquilo C3-C6,-alquilo C1-C4, y haloalquilo C1-C4, siendo tambien posible que dos radicales Rb esten unidos a atomos de carbono adyacentes de Ar para formar conjuntamente alquileno C3-C4; R1 es hidrogeno, alquilo C1-C4, haloalquilo C1-C4, cicloalquilo C3-C6, cicloalquilo C3-C6, cicloalquilo C3-C6-alquilo C1-C4, hidroxialquilo C1-C4, alcoxi C1-C4, alquenilo C3-C4 o alquenilo C3-C4; con los radicales n, R1, R2, R3, R4 y R5, que tienen los significados proporcionados en las reivindicaciones de la patente, a los oxidos de nitrogeno y a las sales de adicion de acido fisiologicamente toleradas de estos compuestos y a composiciones farmaceuticas que comprenden al menos un compuesto de N-[(piperazinil)hetaril]arilsulfonamida de conformidad con lo reclamado en cualquiera de las reivindicaciones 1 a 10 y/o al menos una sal de adicion de acido fisiologicamente tolerada de I y/o un oxido de nitrogeno de I, en caso apropiado conjuntamente con vehiculos farmaceuticamente aceptables y/o sustancias auxiliares para el tratamiento de enfermedades que responden a la influencia por antagonistas o agonistas de receptor D3 de dopamina, en particular para el tratamiento de enfermedades del sistema nervioso central y perturbaciones de la funcion hepatica.
MXPA05010986A 2003-04-14 2004-04-13 Compuestos de n-[(piperazinil)hetaril]arilsulfonamida con afinidad para el receptor d3 de la dopamina. MXPA05010986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/413,233 US20040204422A1 (en) 2003-04-14 2003-04-14 N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
PCT/EP2004/003872 WO2004089905A1 (en) 2003-04-14 2004-04-13 N-[(piperazinyl)hetaryl]arylsulfonamide compounds with affinity for the dopamine d3 receptor

Publications (1)

Publication Number Publication Date
MXPA05010986A true MXPA05010986A (es) 2005-12-15

Family

ID=33131380

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010986A MXPA05010986A (es) 2003-04-14 2004-04-13 Compuestos de n-[(piperazinil)hetaril]arilsulfonamida con afinidad para el receptor d3 de la dopamina.

Country Status (17)

Country Link
US (3) US20040204422A1 (es)
EP (1) EP1613596B1 (es)
JP (1) JP4864694B2 (es)
KR (1) KR101124911B1 (es)
CN (1) CN1805937B (es)
AT (1) ATE388939T1 (es)
AU (1) AU2004228354B2 (es)
BR (1) BRPI0409374A (es)
CA (1) CA2522319C (es)
DE (1) DE602004012400T2 (es)
ES (1) ES2303065T3 (es)
IL (1) IL171421A (es)
MX (1) MXPA05010986A (es)
NZ (1) NZ543101A (es)
PL (1) PL1613596T3 (es)
WO (1) WO2004089905A1 (es)
ZA (1) ZA200509122B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
EP1651605B1 (en) * 2003-07-29 2012-05-02 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
GB0412072D0 (en) * 2004-05-28 2004-06-30 Syngenta Participations Ag Chemical compounds
AU2005302514A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Cyclohexyldiamines as selective alpha 1a/1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms
FR2878524B1 (fr) * 2004-12-01 2007-01-19 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
DE602005021150D1 (de) * 2004-12-03 2010-06-17 Hoffmann La Roche 3-substituierte pyridinderivate als h3-antagonisten
RU2386618C2 (ru) * 2004-12-16 2010-04-20 Ф.Хоффманн-Ля Рош Аг Производные пиперазинилпиридина в качестве агентов против ожирения
PE20080176A1 (es) * 2006-03-31 2008-04-25 Glaxo Group Ltd Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)
TW200808762A (en) * 2006-04-19 2008-02-16 Abbott Gmbh & Co Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
AU2008320875B2 (en) * 2007-10-31 2013-08-01 Abbvie Deutschland Gmbh & Co Kg Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
WO2010040274A1 (zh) 2008-10-10 2010-04-15 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体，其制备方法及其医药用途
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
EP3821947A1 (en) * 2019-11-13 2021-05-19 Libra Therapeutics, Inc. Heterocyclic trpml1 agonists

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE4425145A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE4425146A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
JP4327915B2 (ja) * 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
HUP0102732A3 (en) * 1998-04-20 2002-12-28 Basf Ag Substituted amids, their use for producing pharmaceutical compositions and pharmaceutical compositions containing them
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
MXPA02003420A (es) * 1999-10-06 2002-08-20 Basf Ag Inhibidores de la via de senalizacion de endotelina y antagonistas de los receptores de alfav°3 integrina para el tratamiento en combinacion.
DE10040051A1 (de) * 2000-08-11 2002-02-21 Basf Ag Derivate des 4-(Trifluormethyl)-phenols sowie Derivate des 4-(Trifluormethylphenyl)-2-(tetrahydropyranyl)ethers und Verfahren zu ihre Herstellung
DE10131543A1 (de) 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
GB0211005D0 (en) * 2002-05-15 2002-06-26 Ipwireless Inc System,transmitter,receiver and method for communication power control
WO2004058265A1 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors
DE10304870A1 (de) * 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
MXPA05008441A (es) * 2003-02-14 2005-10-19 Wyeth Corp Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6.
DE10311065A1 (de) * 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
US7320979B2 (en) * 2003-04-14 2008-01-22 Abbott Gmbh & Co. Kg. N-[(piperazinyl)hetaryl]arylsulfonamide compounds
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
US20050113576A1 (en) * 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
DE10358004A1 (de) * 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
DE102004027358A1 (de) * 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
EP1809597B1 (en) * 2004-10-14 2012-01-11 Abbott GmbH & Co. KG Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
BRPI0515998A (pt) * 2004-10-14 2008-08-19 Abbott Gmbh & Co Kg compostos heterocìclicos adequados para tratar desordens que respondem à modulação do receptor d3 de dopamina
KR20070106989A (ko) * 2004-12-02 2007-11-06 애보트 게엠베하 운트 콤파니 카게 도파민 ｄ₃ 수용체의 조정에 반응하는 장애의 치료에적합한 트리아졸 화합물

Also Published As

Publication number Publication date
NZ543101A (en) 2009-02-28
US8476275B2 (en) 2013-07-02
CA2522319A1 (en) 2004-10-21
US20040204422A1 (en) 2004-10-14
CA2522319C (en) 2013-10-15
DE602004012400D1 (de) 2008-04-24
ZA200509122B (en) 2007-04-25
US20070054918A1 (en) 2007-03-08
US20110294817A1 (en) 2011-12-01
EP1613596A1 (en) 2006-01-11
ATE388939T1 (de) 2008-03-15
IL171421A (en) 2012-03-29
CN1805937A (zh) 2006-07-19
CN1805937B (zh) 2012-07-11
WO2004089905A1 (en) 2004-10-21
PL1613596T3 (pl) 2008-09-30
AU2004228354B2 (en) 2010-04-22
AU2004228354A1 (en) 2004-10-21
BRPI0409374A (pt) 2006-04-25
EP1613596B1 (en) 2008-03-12
KR101124911B1 (ko) 2012-03-27
ES2303065T3 (es) 2008-08-01
KR20060005367A (ko) 2006-01-17
JP2006522769A (ja) 2006-10-05
JP4864694B2 (ja) 2012-02-01
DE602004012400T2 (de) 2009-04-02

Similar Documents

Publication Publication Date Title
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
MXPA05010986A (es) Compuestos de n-[(piperazinil)hetaril]arilsulfonamida con afinidad para el receptor d3 de la dopamina.
TW200517109A (en) Substituted pyridinones
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
MXPA05010621A (es) Pirimidinonas sustituidas.
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
GEP20105053B (en) Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
MXPA04003007A (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
MY156747A (en) Isoxazolo-pyridine derivatives
MX2010006182A (es) Derivados de isoxazolo-piridazina.
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
FR2844268B1 (fr) Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
TW200504070A (en) 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
MXPA05010112A (es) Derivados 8-perfluoroalquil-6, 7, 8, 9-tetrahidropirimido [1,2-a] pirimidin-4 -ona substituidos.
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights